Related Experiment Video
Updated: Jan 11, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Recent advances in nanoparticles-based sonodynamic and immune checkpoint blockade synergistic therapy for pancreatic
Haijie Li1,2,3, Ying Lei1,2,3, Yunqing Tian1,2,3
1Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710127, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) represents a major clinical challenge due to its dense fibrotic stroma, hypovascular characteristics, and immunosuppressive tumor microenvironment (TME), which collectively hinder effective drug delivery and contribute to recurrence and metastasis. The TME not only restricts therapeutic penetration but also compromises antitumor immune responses through multiple immunosuppressive mechanisms, thereby constituting a central obstacle in PDAC treatment. Nanoparticles (NPs)-mediated sonodynamic therapy (SDT) offers several advantages, including enhanced tissue penetration, improved biosafety profiles, and reactive oxygen species (ROS)-independent tumor-killing mechanisms. Nevertheless, the limitation to tumor inhibition instead of shrinkage and the incapability of eliminating metastatic tumors hinder the clinical potential for SDT. Fortunately, immune checkpoint blockade (ICB) can revive immunological function and induce a long-term immune memory against tumor rechallenges. Therefore, the synergistic combination of NP-based SDT with ICB presents a promising strategy for improving therapeutic outcomes in PDAC. This review provides an overview of the fundamental principles underlying ultrasonic cavitation, sonodynamic effects, sonosensitizer classification, and ICB mechanisms. This review highlighted the synergistic anti-tumor mechanisms and summarized the representative preclinical trials on SDT-assisted immunotherapy. Furthermore, this work explores the molecular basis of SDT-ICB synergy from the perspective of TME complexity. In addition, current nanomedicine engineering approaches aimed at overcoming stromal barriers in pancreatic tumors are critically evaluated. Finally, key challenges and future directions for the development of this combinatorial therapeutic strategy are discussed, offering novel perspectives on the application of biomaterials in advanced cancer therapy.
Insights
Combining nanoparticle-based sonodynamic therapy (SDT) with immune checkpoint blockade (ICB) shows promise for pancreatic cancer. This synergistic approach aims to overcome tumor microenvironment barriers and enhance treatment efficacy against pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Nanomedicine
- Immunotherapy
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents significant treatment challenges due to its dense stroma, hypovascularity, and immunosuppressive tumor microenvironment (TME).
- The TME restricts drug delivery and impairs anti-tumor immune responses, hindering effective cancer therapy.
- Current treatments, including sonodynamic therapy (SDT), face limitations in tumor shrinkage and metastatic disease eradication.
Purpose of the Study:
- To review the principles of SDT and immune checkpoint blockade (ICB) for pancreatic cancer.
- To explore the synergistic anti-tumor mechanisms of combining SDT with ICB.
- To evaluate nanomedicine strategies for overcoming stromal barriers and discuss future directions for SDT-ICB therapy in PDAC.
Main Methods:
- Review of fundamental principles of ultrasonic cavitation, sonodynamic effects, sonosensitizers, and ICB mechanisms.
- Analysis of synergistic anti-tumor mechanisms and preclinical trials of SDT-assisted immunotherapy.
- Exploration of TME complexity and nanomedicine approaches for pancreatic tumors.
Main Results:
- SDT offers enhanced tissue penetration and ROS-independent tumor killing, but has limitations in tumor shrinkage and metastatic control.
- ICB can restore anti-tumor immunity and induce long-term immune memory.
- The combination of NP-based SDT and ICB demonstrates a promising synergistic strategy for PDAC treatment.
Conclusions:
- The synergistic combination of nanoparticle-based SDT and ICB presents a promising strategy to overcome PDAC's TME challenges.
- Understanding the molecular basis of SDT-ICB synergy within the TME is crucial for optimizing therapeutic outcomes.
- Further development of nanomedicine and biomaterials is essential for advancing this combinatorial therapy in pancreatic cancer treatment.
More Related Videos
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...